Verrica Pharmaceuticals Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Verrica Pharmaceuticals Inc. (VRCA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $8.98 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $10.18, a 118.92% increase year-over-year.
- Verrica Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $4.65, a 11.26% decline year-over-year.
- Verrica Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $5.24, a 54.87% decline year-over-year.
- Verrica Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $11.61, a 1.28% decline year-over-year.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month |
|---|---|---|---|
| 2026-06-30 | $8.98 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $10.18 10-Q · filed 2026-05-12 | ||
| 2025-09-30 | $22.18 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | $25.12 10-Q · filed 2025-08-12 | ||
| 2025-03-31 | $4.65 10-Q · filed 2025-05-13 | ||
| 2024-09-30 | $6.37 10-Q · filed 2024-11-05 | ||
| 2024-06-30 | $6.12 10-Q · filed 2024-08-14 | ||
| 2024-03-31 | $5.24 10-Q · filed 2024-05-13 | ||
| 2023-03-31 | $11.61 10-Q · filed 2023-05-09 | ||
| 2022-09-30 | $10.27 10-Q · filed 2022-11-07 | ||
| 2022-06-30 | $10.36 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | $11.76 10-Q · filed 2022-05-09 | ||
| 2021-09-30 | $13.81 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | $14.64 10-Q · filed 2021-08-10 | ||
| 2021-03-31 | $14.64 10-Q · filed 2021-05-07 | ||
| 2020-09-30 | $10.78 10-Q · filed 2020-11-09 | ||
| 2020-06-30 | $15.13 10-Q · filed 2020-08-05 | ||
| 2020-03-31 | $15.13 10-Q · filed 2020-05-07 | ||
| 2019-06-30 | $8.87 10-Q · filed 2019-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |